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Aim: This study assesses the cost-effectiveness of secukinumab vs currently licensed biologics 
for the treatment of ankylosing spondylitis (AS) from the Finnish health care system perspective.
Methods: A semi-Markov model compared secukinumab with adalimumab, adalimumab 
biosimilar, certolizumab pegol, etanercept, etanercept biosimilar, golimumab, and infliximab 
in a biologic-naïve population over a lifetime horizon. The Bath Ankylosing Spondylitis Dis-
ease Activity Index (BASDAI) was used to assess the treatment response. Efficacy inputs were 
obtained from the network meta-analysis, and other model inputs were obtained from the pub-
lished literature and Finnish sources. Main study outcomes included quality-adjusted life years 
(QALYs) gained and incremental cost-effectiveness ratio in terms of cost per QALY gained. 
Robustness of results was confirmed by sensitivity analyses and alternative scenario analyses.
Results: Secukinumab achieved highest QALYs (13.1) at lowest expected lifetime cost 
(€279,872) vs other comparators in biologic-naïve AS patients in the base case analysis, thus 
it dominated other biologics. Golimumab had a second highest QALYs (12.9) at the total cost of 
€309,551. Results were sensitive to variation in BASDAI 50 response for secukinumab, base-
line Bath Ankylosing Spondylitis Functional Index (BASFI) score across all drugs, change in 
BASDAI and BASFI scores, and discount rates as observed in the one-way sensitivity analyses. 
Secukinumab was either dominant or cost-effective treatment in different alternative scenarios.
Conclusion: Secukinumab presented itself to be the dominant (ie, less costly and more effec-
tive) treatment vs other comparators for the biologic-naïve patients with AS in Finland.
Keywords: radiographic axial SpA, secukinumab, cost-effectiveness, Finland, economic evalu-
ation, health economics, IL-17, anti-TNF 
Introduction
Ankylosing spondylitis (AS) is a chronic, systemic, inflammatory disease that affects 
primarily the sacroiliac joints and spine and leads to back pain, stiffness, discomfort, 
fatigue, impaired spinal mobility, and postural abnormalities.1 AS can also inflame 
peripheral joints and entheses2 and has extra-articular manifestation.3 The New York 
classification criteria for AS require radiographic sacroiliitis, which may take many 
years to develop, and hence the diagnosis as well as disease management is often 
delayed. The epidemiological data for AS are scarce in Finland. The annual incidence 
of AS or nonradiographic axial spondyloarthritis patients requiring advanced treat-
ments beyond NSAIDs has been 17 per 100,000 adults during 2012–2014 in Finland.4
AS manifests itself usually in early adulthood (particularly during the third decade 
of life) and impacts patients for most of their life. AS is associated with decreased 
quality of life (QoL), increased mortality, and substantial health care-related costs, 
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making it a burden to the patient and society.5 The AS-related 
costs were reported to vary across the European countries, 
and indirect costs contribute to the major component of the 
total costs ranging from 53.4% to 62%. Also, as the disease 
severity increases, direct costs increase two times while 
indirect costs increase almost four times.6
As per the recently updated treatment recommenda-
tions (2016) from ASAS and the European League Against 
Rheumatism,7 NSAIDs and physical therapy have been 
recommended as first-line treatment for AS; however, the 
disease becomes refractory to these agents over time.8–10 The 
use of anti-tumor necrosis factor (anti-TNF) biologics or 
IL-17A inhibitor is recommended in axial spondyloarthritis 
after the failure of NSAIDs. In Finland, however, biologic 
drugs are unfortunately not reimbursed until at least one 
traditional disease-modifying antirheumatic drug (DMARD) 
(sulfasalazine and methotrexate) has been tried or if DMARD 
is contraindicated.11
Despite major improvement in treatment results with 
the adoption of anti-TNFs, up to 40% of the patients do 
not respond sufficiently to or tolerate anti-TNFs or efficacy 
may reduce over time,12 indicating a significant unmet medi-
cal need in the treatment of AS patients. If patients are not 
responsive to initial biologic therapy, it is recommended to 
switch a second anti-TNF or secukinumab.7 These updated 
recommendations also include an overarching principle that 
addresses the cost issues with AS for the very first time. It 
highlights the need for “best care” along with the use of 
cost-effectiveness analyses results while making treatment 
decisions.
Secukinumab is the first and fully human recombinant 
antihuman IL-17A IgG1 monoclonal antibody, which is 
licensed for use in AS.8 Secukinumab was approved by Euro-
pean Medicines Agency (EMA) in 2015 for the treatment 
of adult patients with active AS who have responded inad-
equately to conventional therapy.13 Secukinumab is a highly 
efficacious treatment for AS providing sustained improve-
ment in AS signs and symptoms, a rapid onset of action, and 
a favorable safety profile compared with placebo according to 
the results of multiple phase 3 clinical trials.14–17 Additionally, 
secukinumab has demonstrated superior efficacy in indirect 
comparison methods (matching-adjusted indirect comparison 
[MAIC],18 network meta-analysis [NMA]).19
This analysis reports the results of a cost-effectiveness 
study of secukinumab in patients with AS who have not 
been previously treated with any biologic (biologic-naïve) in 
Finland. Additionally, cost-effectiveness of secukinumab was 
also analyzed in mixed population (a combination of both 
biologic-naïve and biologic-experienced patients [patients 
who had been previously treated with biologics]) in the 
alternative scenario analysis.
Methods
Patient population and interventions
Adult AS patients (18 years or older) fulfilling the modified 
New York criteria for AS and having inadequate response 
to NSAIDs were included in the analysis. The patients who 
were naïve to biologic therapy were considered for the 
base-case analysis. For an alternate analysis, secukinumab 
150 mg results were also analyzed in mixed population (a 
combination of both biologic-naïve and biologic-experienced 
patients). Population data inputs were obtained as weighted 
average across all patients from the MEASURE 1 and MEA-
SURE 2 pooled trial data (Table S1).
The model evaluated the cost-effectiveness of subcutane-
ous (s.c.) secukinumab 150 mg compared with the currently 
licensed biologics (s.c. treatments adalimumab and its bio-
similar, certolizumab pegol, etanercept and its biosimilar, 
golimumab and intravenous [i.v.] infliximab) for the treatment 
of AS from the Finnish health care system perspective. The 
list of dose and dosage frequencies of the treatments for this 
analysis is listed in Table S2. These are based on the EMA 
authorization approval.20
Model structure
A semi-Markov model was developed using Microsoft Excel 
(Figure 1). The semi-Markov model structure was chosen due 
to time-dependent probabilities associated with mortality, 
unlike standard Markov model where transition probabilities 
are constant over time. In the model, patients start a given 
treatment and response to the treatment was assessed at the 
end of 3 months by considering a 50% improvement from 
baseline in the initial Bath Ankylosing Spondylitis Disease 
Activity Index (BASDAI 50) response. Previous economic 
evaluations of anti-TNFs in AS considered similar model to 
assess the treatment response.21
Patients transitioned to different health state based on 
the probabilities of BASDAI response rate, malignancy, 
chance of serious infection, dropout rate, and death (Figure 
1). Adverse events (AEs) such as serious infection (includ-
ing tuberculosis) and malignancy were included as separate 
health states to better track the associated costs and QoL 
effects. Patients who experienced infections were allowed to 
continue biologic treatment or switch to conventional care. 
In contrast, patients discontinued biologic treatment upon 
entering the “malignancy” health state. Patients in “malig-
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nancy” state were assumed to be at a higher mortality risk 
for 5 years into that state.
Patients withdrawing from initial biologic treatment 
were treated long-term with the subsequent biologic ther-
apy. Considering data on the effectiveness of subsequent 
biologics were limited; average values of efficacy, treat-
ment withdrawal rates, cost, and AE rates were used for 
all biologics. Patients receiving subsequent-line biologics 
either stayed on the treatment for rest of time horizon or 
could drop out to conventional care. Since there was no 
discontinuation rate available for patients dropping out 
from subsequent-line biologic to conventional therapy, it 
was assumed minimum of annual dropout rate from year 
2 onward of all biologics (ie, annual dropout rate of 1.6% 
was applied for transition from second-line treatment to 
conventional care, see Table S3).
Model inputs
Clinical inputs
Comparative effectiveness data for treatments were obtained 
from a Bayesian fixed effects NMA,22 which included a total 
of seven trials with 1,361 biologic-naïve patients. The main 
clinical input was BASDAI 50 response at 3 months, which 
was used as primary response criteria (Table 1). Although 
the use of Ankylosing Spondylitis Disease Activity Score 
(ASDAS) as a primary response criteria measure was dis-
cussed when building the model, there are no sufficient data 
from trials available from different anti-TNFs to establish 
a sufficient data basis for a valid health economic model. 
Also, ASDAS is closely related to BASDAI, as three out of 
the six BASDAI items are used to calculate ASDAS and a 
study by Eder et al found that ASDAS was not superior to 
BASDAI in its ability to discriminate between high and low 
disease activity states in AS.23 Moreover, the use of BASDAI 
50 is consistent with existing British Society of Rheumatol-
ogy guidelines24 and the National Institute for Health and 
Care Excellence appraisals for AS.25,26 Additional clinical 
inputs included short-term changes in BASDAI and Bath 
Ankylosing Spondylitis Functional Index (BASFI) scores for 
responders and nonresponders (Table 2), long-term changes 
in BASFI captured through modified Stoke Ankylosing 
Spondylitis Spinal Score (Table 3), and biologic withdrawal 
rates (which were treatment specific and obtained for year 1 
as well as year 2 and beyond) (Table S3).
Start
Tx
12 weeks
Maintenance
Tx
Second-line Tx
Infection |
Maintenance
Tx
Infection |
Second-line Tx
Malignancy
Death
BASDAI 50
Yes
No
Dropouts
Dropouts
Values (efficacy, safety, costs) of
second-line Tx estimated as weighted
average of those for other
biologics
Conventional care
Induction period
History of
malignancy
Figure 1 Markov model structure with 3-month induction period.
Abbreviations: Tx, treatment; BasDai, Bath ankylosing spondylitis Disease activity index.
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Resource utilization and cost data
Four types of direct medical costs were incorporated in the 
model: drug acquisition costs, disease-related costs, medical 
support costs, and AE costs. Local unit costs were valued 
using public health care cost index, and where needed, costs 
were inflated per the 2017 exchange rate for Euro (Tables S4 
and S6). The drug acquisition costs for secukinumab 150 mg 
and for brand comparators (Table 4) were obtained from the 
Finnish medicinal products and price database.27 Biosimilar 
pricing for etanercept and adalimumab was assumed to be 
30% less than brand; as they were not, at the time of analyses, 
Table 1 BasDai 50 response at 3 months in biologic-naïve 
patients
Administration Treatment Biologic-naïve
subcutaneous secukinumab 41.53%
Certolizumab pegol 44.20%
Etanercept 36.80%
adalimumab 48.85%
golimumab 47.20%
intravenous Infliximab 44.20%
Notes: BASDAI 50 response data are from a Bayesian fixed effects network 
meta-analysis.22 Biologic-naïve data for certolizumab pegol and infliximab were not 
available and were assumed equivalent to average of other biologics in the network 
meta-analysis 
Abbreviation: BasDai, Bath ankylosing spondylitis Disease activity index.
Table 2 short-term changes in BasDai and BasFi in biologic-naïve patients
Measure Patient group SEC CER P ETN ADA INF GOL
Change in BasDai Respondersa –4.60 –5.57 –4.47 –4.56 –7.94 –5.32
nonresponders –1.01 –1.28 –1.02 –0.81 –1.82 –1.37
Change in BasFi Responders –3.75 –3.59 –3.44 –3.15 –3.96 –4.07
nonresponders –1.17 –0.89 –0.85 –0.78 –0.98 –0.71
Notes: Bayesian fixed effects network meta-analysis.22 aResponders are those who showed BasDai 50 response. Change in BasDai data for biologic-naïve patients was not 
available for sEC and CER P and was assumed to be equivalent to the average of other biologics in the nMa. Change in BasFi data for biologic-naïve patients for CER P was 
not available and was assumed to be equivalent to the average of other biologics in the nMa (excluding sEC).
Abbreviations: aDa, adalimumab; as, ankylosing spondylitis; BasDai, Bath ankylosing spondylitis Disease activity index; BasFi, Bath ankylosing spondylitis Functional 
Index; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; NMA, network meta-analysis; SEC, secukinumab.
Table 3 long-term changes in BasFi
Input Mean Sources
annual rate of msasss change for msasss ≥10 1.440 Corbett et al (2014)28
BasFi change associated with 1 unit change in msasss 0.057 Corbett et al (2014)28
Biologic treatment effect on progression for comparators 0.420 Corbett et al (2014)28
Biologic treatment effect on progression for secukinumaba 0.153 Calculated from MEasURE 1 trial data and using overall 
background progress rate from Ramiro et al (2015)50
Time to treatment effect (years) 0 assumption
Notes: The long-term changes in BasFi were assessed by progression of radiographic disease measured by msasss score. aThis figure was calculated using the overall 
background progression rate of 0.98 units/year from the study by Ramiro et al (2015)50 and the MEASURE 1 week 104 mSASSS progression figure of 0.3.
Abbreviations: BASFI, Bath Ankylosing Spondylitis Functional Index; mSASSS, modified Stoke Ankylosing Spondylitis Spine Score.
Table 4 Drug acquisition costs for biologics in Finland
Administration Drug Dose 
(mg)
Cost Unit Number of doses 
(first 3 months)
subcutaneous secukinumab 150 €584.43 Per prefilled syringe 7.00
Certolizumab pegol 200 €483.07 Per prefilled syringe 10.00
Etanercept 50 €260.04 Per prefilled syringe 13.00
Etanercept biosimilar 50 €182.02 Per prefilled syringe 13.00
adalimumab 40 €527.41 Per prefilled syringe 7.00
adalimumab biosimilar 40 €369.19 Per vial 7.00
golimumab 50 €1,086.93 Per prefilled syringe 3.00
intravenous Infliximab 100 €436.06 Per vial 3.00
Notes: Finnish medicinal products and price database.27 all prices exclude value added tax. Retail price for s.c. products and wholesale price for i.v. products are applied 
according to local guidelines. Infliximab price was calculated as a weighted average according to market shares of originator drug and biosimilars. Additionally, a cost of €382 
(2016 value) was considered for each i.v. administration.51 Biosimilar pricing for etanercept and adalimumab was assumed to be 30% less than brand; they are not available in 
the market and thus, only used for sensitivity analysis.
Abbreviations: i.v., intravenous; s.c., subcutaneous.
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available in the market and were only used for sensitivity 
analysis. Additional drug administration costs were con-
sidered for i.v. administration of infliximab compared with 
other s.c. treatments.
Disease-related costs account for the AS disease manage-
ment costs incurred. These costs are estimated based on an 
exponential BASFI regression model:28 Cost (€)=1,508.99 
€ × EXP (0.213 BASFI). Costs were calculated for 3 months 
according to the model cycle length.
Costs associated with medical support resources are 
presented in Table S4. Incidence of AEs and cost per 
event are available in supplementary materials (Tables S5 
and S6).
Other inputs
Utility weight inputs were used to calculate quality-adjusted 
life years (QALYs) to reflect the improvement in QoL expe-
rienced by patients who achieve various levels of BASDAI 
and BASFI response. A linear mixed model was used to 
fit EuroQol 5-dimensions questionnaire utility score as a 
response variable, and BASDAI and BASFI scores, age, and 
sex as predictors. The coefficients for the regression equation 
were taken from the MEASURE 1 and MEASURE 2 pooled 
trial data (Table S7).
Three types of mortality risks were included in the analy-
sis. Patients with AS have higher mortality rates compared 
with the general population. Disease-specific mortality was 
included as relative risks to account for patients having 
mortality vs the general population29 (Table S8). In addition, 
the increased risk of mortality due to AEs, such as serious 
infection or tuberculosis and malignancy, was obtained from 
the literature30 (Table S8). All-cause age-related mortality was 
estimated using National Life Tables for Finland (Statistics 
Finland, 2015).31
Base-case analysis
The primary effectiveness outcome was QALY. Total costs 
and QALYs were estimated for all treatments. First, it was 
checked if secukinumab is a dominant treatment option 
(having higher QALYs at a lower cost vs comparators). In 
case of nondominance, an incremental cost-effectiveness 
ratio was reported.32
The primary analysis was conducted in biologic-naïve 
population for 60 years of time horizon (lifetime) to account 
for the chronic nature of the disease. BASFI rebound was 
assumed to occur according to “natural history” for patients 
who discontinue biologic therapy. Annual discount rates were 
applied at 3% for both costs and outcomes, from the second 
year onward. The base-case analysis was done from a Finnish 
payer perspective; hence, only direct costs were included.
sensitivity analysis
Three different sensitivity analyses (probabilistic, determin-
istic, and alternative scenario analyses) assessed the impact 
of changes in the input parameters on outcomes.
In the one-way sensitivity analysis, one parameter is 
varied at a time using lower and upper bounds of 95% CI, 
and their effects on results were estimated. Inputs and distri-
bution used for each parameter in base-case population are 
shown in Table S9.
A probabilistic sensitivity analysis evaluated the impact 
of simultaneous variation in clinical outcome and resource 
utilization parameters on the model results. The results of the 
probabilistic sensitivity analysis were presented using cost-
effectiveness acceptability curves calculated from the net 
monetary benefit statistic across a wide range of willingness-
to-pay (WTP) thresholds. Also, it allows for the comparison 
of all treatment regimens simultaneously for each scenario.
Various alternative scenarios were analyzed using fol-
lowing alternative settings or input values: mixed population 
(biologic-naïve and experienced), alternative BASFI rebound 
assumption, AE disutilities, utilities sourced from McLeod 
et al,33 inclusion of indirect costs, and exclusion of disease-
specific costs.
Results
Base-case results
Secukinumab 150 mg was compared with the other biologics 
to assess its cost-effectiveness in the biologic-naïve popula-
tion. Patients treated with secukinumab 150 mg achieved 
highest expected QALYs of 13.1 at lowest expected total 
cost (€279,872) in comparison with all other comparators 
when considering 60 years of time horizon (Table 5). In addi-
tion, patients treated with secukinumab had better treatment 
outcomes; they spent more time (27.9 years) in the BASDAI 
50 response state than patients in other biologics. Time spent 
in the BASDAI 50 response state corresponds to the time 
patients spend on maintenance treatment after exhibiting 
treatment response.
Apart from total costs, disaggregated cost components 
(drug costs, administration costs, disease-related costs, and 
AE-related costs) that contribute to the total costs for each 
treatment are also presented in supplementary materials 
(Table S10). Post-discontinuation costs associated with drug, 
disease, administration, and monitoring were much lower for 
patients who started on secukinumab vs other biologics, lead-
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ing to the lower total costs for secukinumab when compared 
with other biologics.
Overall, secukinumab was less costly and more effective 
than the comparators and presented itself to be a dominant 
treatment for biologic-naïve patients with AS in Finland. The 
QALYs gained and corresponding total direct costs of other 
biologic treatment options considered are presented in Table 5.
sensitivity analysis
One-way sensitivity analysis
In one-way sensitivity analysis, BASDAI 50 for secukinumab, 
baseline BASFI score for nonresponders across all drugs, 
change in BASDAI and BASFI scores in responders, and 
discount rates had the highest impact on incremental NMB 
across all biologics at WTP of €30,000 (Figure S1).
Probabilistic sensitivity analyses
In the probabilistic sensitivity analysis, secukinumab 150 mg 
had the highest probability of being cost-effective vs other 
comparators at different WTP thresholds in the biologic-naïve 
population (Figure 2). The probability of secukinumab being 
cost-effective was 98% at WTP levels of €20,000  per QALY 
gain. Additionally, secukinumab had 95%, 87%, and 75% 
probability of being cost-effective at other WTP thresholds 
of €30,000, €50,000, and €100,000 per QALY gained, 
respectively (Figure 2). The means of the total QALYs, total 
cost, and NMB are summarized in supplementary materi-
als (Table S11). Comparing the means of costs and QALYs 
from probabilistic sensitivity analysis with base-case results 
showed minimal difference, indicating the robustness of the 
results and lower uncertainty in the parameters.
scenario analyses
Results for the following scenarios are presented: overall popu-
lation including a mix of biologic-naïve and experienced AS 
patients, alternative BASFI rebound assumption, an analysis 
with AE disutilities, an analysis assuming utilities sourced from 
McLeod et al, indirect costs, and disease-specific costs (Table 6).
In one of the alternative scenario analysis done on 
mixed population (naïve and experienced biologic users), 
Table 5 health outcomes, direct costs, and iCER for secukinumab 150 mg vs comparators over a lifetime horizon (60 years)
Administration Treatment Total 
costs 
(€)
QALYs Time spent in BASDAI 
50 responder state
(in years)
ICER
(secukinumab vs 
comparator)
subcutaneous secukinumab 279,872 13.1 27.9
Certolizumab pegol 309,257 12.6 26.7 secukinumab dominates
Etanercept 305,883 12.1 25.9 secukinumab dominates
Etanercept biosimilar 300,075 12.1 25.9 secukinumab dominates
adalimumab 312,139 12.5 26.5 secukinumab dominates
adalimumab biosimilar 297,282 12.5 26.5 secukinumab dominates
golimumab 309,551 12.9 27.1 secukinumab dominates
intravenous Infliximab 316,291 12.6 26.2 secukinumab dominates
Abbreviations: BasDai, Bath ankylosing spondylitis Disease activity index; iCER, incremental cost-effectiveness ratio; QalYs, quality-adjusted life years.
Table 6 alternative scenario analyses: cost-effectiveness results for secukinumab vs other biologics by varying base-case assumptions
Parameters Base case Scenarios tested Results
Population Biologic naïve Biologic-naïve and biologic-
experienced population
similar to base casea
Utility MEasURE 1 
and 2 trial data
Mcleod et al (2007)33 similar to base casea
Disutility not included included similar to base casea
BasFi rebound 
assumptionb
natural 
history
initial gain similar to base casea
indirect costs not included included secukinumab dominates all branded biologics 
and was cost-effective against biosimilars
Disease-specific costs included Excluded similar to base casea
Notes: asimilar to base-case results, means secukinumab 150 mg dominates all its comparator with higher QalYs and lower costs. bBasFi can be assumed to deteriorate 
in two ways: 1) rebound equal to gain: BasFi deteriorates by the same amount by which it improved when they responded to therapy; 2) rebound back to natural history: 
BasFi deteriorates to the level and subsequent trajectory it would have been had they not initially responded to therapy. Detailed results for all scenarios are available in 
supplementary materials (Tables s12–s17).
Abbreviations: BasFi, Bath ankylosing spondylitis Functional index; QalYs, quality-adjusted life years.
 
Cl
in
ico
Ec
on
om
ics
 a
nd
 O
ut
co
m
es
 R
es
ea
rc
h 
do
wn
lo
ad
ed
 fr
om
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
12
8.
21
4.
14
4.
14
9 
on
 3
1-
M
ay
-2
01
9
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
ClinicoEconomics and Outcomes Research 2019:11 submit your manuscript | www.dovepress.com
Dovepress 
165
Dovepress Purmonen et al
secukinumab 150 mg dominated all its comparators with 
higher QALYs and lower costs. Similarly, in other alternative 
scenarios, except for the scenario including indirect cost, it 
was also observed that secukinumab dominated all its com-
parators with higher QALYs and lower costs (Table 6). In the 
scenario when indirect cost was included, secukinumab domi-
nated all branded biologics and was cost-effective against 
biosimilars. Detailed results regarding alternative scenarios 
are available in supplementary materials (Tables S12–S17).
Discussion
Secukinumab 150 mg dominated all its currently licensed 
comparators (s.c. treatments adalimumab and its biosimilar, 
certolizumab pegol, etanercept and its biosimilar, golim-
umab, and i.v. infliximab) in the treatment of biologic-naïve 
AS patients in Finland.
The analysis was carried out from the perspective of the 
Finnish health care system. Secukinumab 150 mg had better 
health outcomes (calculated in terms of QALYs) at lowest 
total cost, which could be beneficial to the patient and health 
care system as a whole. Model uses multiple parameters like 
BASDAI 50, change in BASDAI, change in BASFI, discon-
tinuation rates, utility values, and safety, and these parameters 
have different impact on the final results. Particularly, factors 
such as AEs and discontinuation rates have a strong impact on 
the lifetime QALYs, leading to higher QALYs for secukinumab 
vs other comparators over 60 years of time horizon. The robust-
ness of the analyses was confirmed by one-way sensitivity 
analyses, probabilistic analyses, and scenario analyses.
This is among the first full-length studies assessing 
cost-effectiveness of secukinumab 150 mg compared with 
other biologics. However, other modeling studies have been 
conducted in different countries such as Canada,34 UK,35,36 
Turkey,37 Colombia,38 Bulgaria,39 and Russia;40 which reported 
similar results. All these studies reported secukinumab to be 
dominant (more effective and less costly) over anti-TNFs in 
biologic-naïve as well as biologic-experienced AS popula-
tion. Across multiple studies, secukinumab resulted in an 
additional 0.20–0.86 QALY gain at a total cost, which was 
€4,644 to €9,134 lower compared with other biologics.34,37,38 
The current study is also the first to assess cost-effectiveness 
of secukinumab in a Finnish context. Thus, these findings 
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Figure 2 Probability of cost-effectiveness of as treatments at different willingness-to-pay thresholds for biologic-naïve patients.
Abbreviations: ADA, adalimumab; AS, ankylosing spondylitis; CER P, certolizumab pegol; ETN, etanercept; GOL, golimumab; INF, infliximab; SEC, secukinumab.
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add important evidence to support the use of secukinumab 
while making a comparison of this new class of biologic to 
anti-TNF agents.
strengths and limitations
The cost-effectiveness model structure and many of its 
assumptions were based on models used in previous assess-
ments of biologics in the treatment of AS. In the absence of 
direct comparative evidence from clinical trials, the rela-
tive efficacy of licensed treatments for AS was evaluated 
through a mixed treatment comparison using NMA, which 
is considered as standard modeling methodology in the field. 
We used a lifetime horizon (60 years) for base-case analysis, 
which is more appropriate to use for chronic disease like AS. 
Moreover, analyses included detailed cost details (such as 
costs for drug acquisition, hospitalization, AEs) to estimate 
economic burden of disease. We also established the robust-
ness of our results through probabilistic and deterministic 
sensitivity analysis.
The current analysis has several limitations. The major 
limitations of this analysis may be related to the scarcity of 
data and the complexity coupled with the long-term duration 
of the disease. There might be a potential underestimation of 
long-term efficacy of secukinumab 150 mg as the effective-
ness data are derived from NMA (with data up to week 16). 
However, an extension of MEASURE trial has established the 
significant clinical efficacy of secukinumab for >3 years in AS 
patients.41 In addition, secukinumab has shown statistically 
significant improvement in efficacy (in terms of ASAS20 and 
40 responses) in comparison with adalimumab in MAIC for 
up to 52 weeks.18
Another limitation of this study is the lack of data in 
all subpopulations for available comparators and the lack 
of efficacy data for subsequent biologic treatment after 
withdrawal from first-line biologic. Thus, data for com-
parators that did not report all necessary subpopulations 
or outcomes were set to those of the average of other bio-
logics in the NMA. Although a country-specific (Finland) 
cost-effectiveness model was built, the globally conducted 
clinical trials were used as a basis for efficacy parameters, 
which could be considered as one of the limitations of the 
present analysis.
The subsequent-line biologic treatment was modeled 
using average values of the efficacy, costs, and AE inci-
dence rates across all biologics in the model. Patients with 
AS are reported to have a significant impairment in work 
productivity.42–44 The base-case analysis did not take into 
account any indirect costs (mainly in the form of produc-
tivity loss) associated with AS; however, indirect cost was 
included as a part of the alternative scenario analysis. In the 
real-world clinical practice, patients having disease remis-
sion or low disease activity can be managed by tapering 
the dose of biologics (by reducing the dose or increasing 
the interval between dosing frequency) to reduce the cost 
of treatment.45–49 However, for secukinumab, such dose 
tapering is not recommended (not part of drug label). We 
would need robust long-term clinical effectiveness data for 
all biologic treatments (including secukinumab) from real-
world settings to enable comparison based on dose tapering. 
Once such data become available for all biologics, it can 
be included in the cost-effectiveness analyses. Currently, 
analysis considered drug withdrawal rates from clinical 
trials. In future, this analysis can also be rerun using drug 
withdrawal rates from long-term registries once such data 
for secukinumab become available.
Conclusion
Secukinumab 150 mg dominated all other biologics (more 
QALYs at lower costs) in the biologic-naïve population in 
Finland for the treatment of AS over a lifetime horizon. This 
analysis implied that secukinumab is the most cost-effective 
biologic option for the treatment of AS patients unresponsive 
to conventional therapy in Finland.
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